Giulio Romeo is an Endocrinology/Metabolic physician affiliated with Joslin Diabetes Center. OpenAlex indexes 74 publications with 4,386 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Joslin Pl
Boston, MA 022155306
Telephone
617-309-2440Provider last certified this registry record 2 Dec 2025.
Clinical trials
- Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes
Sponsor: Joslin Diabetes Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20241 payment
- Abbott LaboratoriesProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
64.7%GLP-1 receptor agonist24.2%Mounjaro52%Ozempic28%Trulicity20%Part D≥23 patientsInsulin Analog19%Lantus Solostar22%Tresiba Flextouch U-10018%Novolog Flexpen17%Toujeo Solostar12%Humalog Kwikpen U-10010%Humalog8%Tresiba Flextouch U-2007%Novolog6%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
19.3%l-Thyroxine17%Levothyroxine Sodium77%Synthroid15%Levoxyl8%Part D<11 patientsThyroid Hormone Synthesis Inhibitor2.3%Methimazole100%Part D<11 patientsCardiovascular
9.9%Statin4.1%Atorvastatin Calcium66%Rosuvastatin Calcium34%Part D<11 patientsAngiotensin receptor blocker (ARB)3.4%Losartan Potassium56%Valsartan44%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Sylvia Rosas, MD
Joslin Diabetes Center
Jason Gaglia, MD
Joslin Diabetes Center
Lloyd Aiello, MD, PhD
Joslin Diabetes Center
Jean Schaffer, MD
Joslin Diabetes Center
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”